Q32 Bio transitioned into a publicly traded corporate entity via a strategic business combination and reverse merger framework, later establishing its prominent presence on the Nasdaq Global Market under the ticker symbol QTTB. The corporate evolution allowed the clinical-stage biopharmaceutical enterprise to access broader public capital markets, facilitating extensive institutional funding rounds, secondary offerings, and private placements to financially support its expanding pipeline of immunology-focused biological treatments.